CK Life Sciences Int'l., (Holdings) Inc. (HKG:0775)
Hong Kong
· Delayed Price · Currency is HKD | Market Cap | 7.02B |
| Revenue (ttm) | 5.41B |
| Net Income (ttm) | -186.81M |
| Shares Out | 9.61B |
| EPS (ttm) | -0.02 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,577,000 |
| Average Volume | 2,800,472 |
| Open | 0.720 |
| Previous Close | 0.730 |
| Day's Range | 0.720 - 0.730 |
| 52-Week Range | 0.640 - 1.100 |
| Beta | 0.38 |
| RSI | 44.20 |
| Earnings Date | May 12, 2026 |
About HKG:0775
CK Life Sciences Int'l., (Holdings) Inc., an investment holding company, researches, develops, manufactures, commercializes, and sells health and agriculture-related products in the Asia Pacific and North America. It manufactures and markets plant protection products and soluble fertilizers; manufactures, blends, distributes, and sells fertilizers, pesticides, and related agricultural products; manufactures and distributes horticultural products for the home gardening market; and produces non-sterile prescription and over-the-counter medicines.... [Read more]
Financial Performance
In 2025, HKG:0775's revenue was 5.41 billion, a decrease of -2.04% compared to the previous year's 5.52 billion. Losses were -186.81 million, 47.6% more than in 2024.
Financial StatementsNews
Li Ka-shing’s CK Life unit eyes China fast track for cancer vaccine pipeline
CK Life Sciences, a unit of Li Ka-shing-backed CK Group, plans to bring its cancer vaccine candidates to mainland China through a “fast track” channel as Beijing moves to accelerate early-stage drug d...
CK Life unit merges with TransCode as Li Ka-shing firm eyes anticancer drugs
CK Life Sciences International is set to merge its subsidiary Polynoma with Nasdaq-listed TransCode Therapeutics, in a move expected to boost the pipeline of anticancer drugs, according to the biotech...
TransCode Acquires Polynoma From CK Life Sciences
(RTTNews) - TransCode Therapeutics (RNAZ) has entered into a definitive agreement to acquire Polynoma, a privately-held biotechnology immuno-oncology company. Polynoma is developing a late-stage candi...
CK Life’s new CEO counts on Big Pharma experience to boost new drug success, earnings
Lance Yuen spent two decades at Bristol-Myers Squibb and Bayer in the region before becoming the CEO at CK Life Sciences last month.